Deeper Cholesterol Lowering Cut First Heart Attacks and Strokes in High-Risk Adults

CATEGORY: HEART & CIRCULATION

Nearly everything proven about the powerful cholesterol-lowering injections called PCSK9 inhibitors came from people who’d already survived a heart attack or stroke. The VESALIUS-CV trial asked whether evolocumab could protect people before that first event, and it did: over a median of 4.6 years, 6.2% of treated patients had a heart attack, stroke, or death from coronary disease, versus 8.0% on placebo, a 25% reduction.¹

High Risk, but No Heart Attack Yet

The trial enrolled 12,257 adults at high cardiovascular risk from artery disease or diabetes, none with a prior heart attack or stroke. All were already on standard cholesterol treatment, mostly statins. Chance alone decided who added evolocumab, an injection every two weeks that blocks PCSK9, a protein that limits how much LDL cholesterol the liver can clear. The drug did what it always does to the blood test: in a substudy, LDL fell from a median of 115 to 45 mg/dL, less than half the placebo group’s level. The question was whether people who hadn’t yet had an event would see that translate into fewer of them.

Three Fewer First Events Per Hundred Patients

They did. Heart attacks alone fell 36%. A broader measure that added artery-opening procedures occurred in 13.4% of the evolocumab group against 16.2% on placebo, roughly three fewer first events for every hundred patients treated across the trial.¹ Adverse events were no more common than with placebo. This was the missing half of the evidence. The earlier FOURIER trial had shown evolocumab prevents repeat events in people with established heart disease.² VESALIUS-CV extends the same logic back one step, to the much larger group hoping never to join them.

Key Takeaways

• Added to statins in high-risk adults with no prior heart attack or stroke, evolocumab cut the risk of heart attack, stroke, or coronary death by a quarter: 6.2% versus 8.0% over about five years.
• Driving LDL cholesterol down to 45 mg/dL proved safe, with side effects matching placebo over 4.6 years.
• These were high-risk patients with artery disease or diabetes; the trial doesn’t speak to adults at average risk.

References

1. Bohula EA, Marston NA, Bhatia AK, et al. Evolocumab in Patients without a Previous Myocardial Infarction or Stroke. N Engl J Med. 2026;394(2):117–127. link
2. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713–1722. link